Green Tea in Breast Cancer Patients

Green Tea Supplement in Women With Incident Breast Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00949923

Enrollment

Registered

2009-07-31

Start date

2008-05-07

Completion date

2016-06-06

Last updated

2018-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incident Breast Cancer

Keywords

Postmenopausal women, Suspicious for breast ca

Brief summary

Prognostic factors for breast cancer beyond stage at diagnosis and tumor characteristics have not been well studied. Of special interest are lifestyle factors that can be modified by women after diagnosis to increase disease-free survival. Green tea is rich in polyphenols consisting primarily of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (EGCG). The investigators hypothesize that there will be a reduction in proliferation and/or an increase in apoptosis in association with short-term EGCG treatment.

Interventions

DIETARY_SUPPLEMENTtea capsule

3 tea capsules daily for 3 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postmenopausal (at least 2 years since last menstrual period) or age 55 or older if prior hysterectomy * Non-current (not with past 6 months) user of menopausal hormones * Mammographic abnormality consistent with any type of incident breast cancer necessitating a diagnostic biopsy (BIRAD IV(b), (c) or V) will be sufficient to draw baseline LFT and complete screening questionnaire. Unless the biopsy confirms incident breast cancer, such subjects will not be included in further research interventions and they will not serve as EGCG treated or control subjects. * Diagnosed with incident breast cancer on the diagnostic biopsy is required for inclusion in the EGCG or control treatment groups. * Non-green tea drinker (less than monthly) - this criteria does not apply to black tea or herbal tea * Provided written informed consent

Exclusion criteria

* Green tea drinker (once per month or more) * History of breast cancer or other cancer including a prior diagnosis of any type of incident breast cancer. * Known allergy to tea * Abnormal liver enzymes (plus or minus 10% of the normal ranges).

Design outcomes

Primary

Measure	Time frame
level of reduction in proliferation or increase in apoptosis in association with short-term EGCG	At surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026